Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study

Abstract Objective To compare the patient-reported outcomes (PROs) and quality of life in patients with HR+/HER2- early breast cancer (EBC) treated with Ribociclib (RIB) and Abemaciclib (ABE) as adjuvant therapy. Methods A multicenter, retrospective cohort study was conducted in Chinese patients rec...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Binbin Cong, Chuanqiang Hou, Changping Shan, Shenyou Sun, Shanping Sun, Chongsheng Xia, Yongsheng Wang
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2026-04-01
סדרה:	BMC Cancer
נושאים:	CDK4/6 inhibitors Early breast cancer HR+/HER2- Patient-reported outcomes RIB ABE
גישה מקוונת:	https://doi.org/10.1186/s12885-026-15983-7
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!